 | Up a level |
Matsusaka, S; Cao, S; Hanna, D L; Sunakawa, Y; Ueno, M; Mizunuma, N; Zhang-Wu, Xiaxia; Yang, D; Ning, Y; Stintzing, S; Sebio, A; Stremitzer, S; Yamauchi, S; Parekh, A; Okazaki, S; Berger, Martin Dave; El-Khoueiry, R; Mendez, A; Ichikawa, W; Loupakis, F; ... (2017). CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics journal, 17(6), pp. 543-550. Nature Publishing Group 10.1038/tpj.2016.59
Studt, J-D; Alberio, L; Angelillo, Anne; Asmis, L M; Fontana, P; Korte, W; Mendez, A; Schmid, P; Stricker, H; Tsakiris, D A; Wuillemin, W A; Nagler, Michael (2017). Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. Journal of thrombosis and haemostasis, 15(8), pp. 1576-1583. Wiley-Blackwell 10.1111/jth.13747
Sunakawa, Y; Cao, S; Berger, Martin Dave; Matsusaka, S; Yang, D; Zhang-Wu, Xiaxia; Ning, Y; Parekh, A; Stremitzer, S; Mendez, A; Okazaki, S; Wakatsuki, T; Azuma, M; Shimada, K; Watanabe, M; Koizumi, W; Wu, A H; Lenz, H-J (2017). Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. Pharmacogenomics journal, 17(1), pp. 36-41. Nature Publishing Group 10.1038/tpj.2015.77
Asmis, L M; Alberio, L; Angelillo-Scherrer, A; Korte, W; Mendez, A; Reber, G; Seifert, B; Stricker, H; Tsakiris, D A; Wuillemin, W A (2011). Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thrombosis research, 129(4), pp. 492-498. Amsterdam: Elsevier 10.1016/j.thromres.2011.06.031
